Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials

Set Alert for Clinical Trials

Juvenescence Raises $100M To Advance Anti-Aging Programs

The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.

Financing StartUps and SMEs

US Is Land Of Opportunity For Zealand

The Danish group is beefing up its operations across the Atlantic as it prepares filings for dasiglucagon and glepaglutide.

Metabolic Disorders Strategy

Interview: Mereo All Set For Key Setrusumab Data

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

Strategy Orthopedics

Mallinckrodt’s Phase III Kidney Failure Trial Hits Primary Endpoint

The data position Mallinckrodt to file for US FDA approval of terlipressin early next year. Mallinckrodt thinks the drug could generate sales of $300m a year, helping it to mitigate its challenges.

Clinical Trials Companies

Regeneron’s Cholesterol Drug Aces Phase III, Teeing Up US FIling

The trial linked ANGPTL3 antibody evinacumab to a steep decline in LDL cholesterol in patients with homozygous familial hypercholesterolemia, setting Regeneron up to file for US FDA approval next year.

Clinical Trials Companies

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial

AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo

The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.

Cancer Clinical Trials

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Clinical Trials Cancer

Ebola Success For Regeneron’s Triple Antibody Cocktail

PALM study stopped early after two agents being tested proved better than ZMapp, the current standard of care, in the ongoing Ebola outbreak in the Democratic Republic of Congo. One is being developed by Regeneron.

Clinical Trials Companies
See All
Advertisement
UsernamePublicRestriction

Register